

October 3, 2023



ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference

BLOOMFIELD HILLS, Mich, Oct. 03, 2023 (GLOBE NEWSWIRE) -- **Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the "Company")**, a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that management will deliver a company presentation and will hold investor meetings at the [8th Annual Dawson James Small Cap Growth Conference](#) being held Thursday, October 12, 2023 at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Fla.

Event: 8th Annual Dawson James Small Cap Growth Conference
Date: Thursday, October 12, 2023
Time: 9:00 a.m. Eastern Time
Location: Wyndham Grand Jupiter at Harbourside Place
Webcast: <https://wsw.com/webcast/dawson8/zivo/2075040>

Investors interested in arranging a meeting with ZIVO management should contact Tirth Patel at LHA Investor Relations at tpatel@lhai.com.

About ZIVO Bioscience

ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.

Forward Looking Statements

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company's product candidate's potential to generate revenues and the expected time frame for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially

different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet our expected demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release and ZIVO undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future.

Contacts:**ZIVO Bioscience**

Keith Marchiando, Chief Financial Officer

(248) 452-9866 x130

kmarchiando@zivobioscience.com

LHA Investor Relations

Tirth T. Patel

(212) 201-6614

tpatel@lhai.com



Source: Zivo Bioscience, Inc.